Op2Lysis
Created in 2016
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
856Activities
Technologies
Entity types
Location
Bd Henri Becquerel, 14000 Caen, France
Caen
France
Employees
Scale: 2-10
Estimated: 8
SIREN
819697707Engaged corporates
5
1 4Added in Motherbase
11 months, 3 weeks ago
biotech Value proposition
A New Hope for Hemorrhagic Stroke
Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North America and Europe.
Cardiovascular, Cérébrovascular, and drug developmentOriginal language
A new hope for cerebral hemorrhage
Op2Lysis développe de nouveaux traitements pour les patients atteints de thromboses au niveau cérébrovasculaire, avec un premier focus sur la forme hemorragique de l’AVC. En effet, il n'y a pas de solution thérapeutique actuellement approuvée et disponible pour les victimes d'un AVC hémorragique. L'entreprise développe sa plateforme NANOp2Lysis(r), l'association d'une technologie de vectorisation de rupture, d'un savoir-faire industriel permettant des productions de qualité clinique, et d'une expertise préclinique incluant la mise en place de modèles prédictifs et translationnels, une première dans ce domaine. O2L-001, le premier produit issu de cette technologie va entrer prochainement en toxicologie réglementaire dans l’objectif d’une demande d’autorisation d’essai clinique chez le patient en Amérique du Nord et en Europe.
Op2Lysis | Innovative treatment for hemorrhagic stroke
Op2lysis is a biotechnology company that develops innovative medicines for the treatment of hemorrhagic stroke, with its proprietary technology NANOp2Lysis®.
https://www.op2lysis.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Omnes Startup accelerator & VC, Financial Services | Omnes Startup accelerator & VC, Financial Services | Other 6 Jul 2024 | | |
 Noshaq Venture Capital and Private Equity Principals | Noshaq Venture Capital and Private Equity Principals | Other 29 Feb 2024 | | |
 WiSEED Crowdfunding, Financial Services | WiSEED Crowdfunding, Financial Services | Other 22 Jan 2024 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 30 Sep 2023 | | |
 Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Medicen Paris Region Public business cluster, French Cluster, Civic and Social Organizations | Other 28 Feb 2024 | | |